Hepatocyte Transplantation

Atta, Shimaa

doi:10.5005/jp-journals-10018-1065

Cited by 2 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, hepatocyte transplantation requires immunosuppression to prevent rejection, which presents an increased risk of infection in compromised patients. (Attia Atta 2013 ; Alwahsh et al 2018 ; Cardoso et al 2018 )…”

Section: Alternative Therapy For Esld: Hepatocyte Transplantationmentioning

confidence: 99%

“…Although the remaining cells could translocate from the sinusoid into the liver parenchyma, only 0.5% of the transplanted hepatocytes engraft into the recipient’s liver, and only a few of those survive and proliferate. (Attia Atta 2013 ; Forbes et al 2015 ) Initially, the liver itself was thought to provide an ideal environment for implanted hepatocytes. However, this led to hepatocyte aggregates in distal portal branches, sinusoids, and central veins resulting in severe portal hypertension and hepatic necrosis.…”

Section: Alternative Therapy For Esld: Hepatocyte Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Inventing Engineered Organoids for end-stage liver failure patients

et al. 2022

View full text Add to dashboard Cite

End-stage liver disease (ESLD) is a term used clinically in reference to a group of liver diseases with liver transplantation as the choice of treatment. Due to the limitations of liver transplantation, alternative treatments are needed. The use of primary human hepatocytes represents a valid alternative treatment, but the limitations related to hepatocyte quality, viability, function, conservation, and storage need to be overcome. Transplanted hepatocytes have only been followed for 6–9 months. Therefore, long-term causes of failures are not yet established, including rejection, apoptosis, or other causes. Other alternative therapies to replace liver transplantation include plasmapheresis, hemodiafiltration, and artificial livers. Unfortunately, these methods are highly limited due to availability, high cost, anaphylaxis reaction, development-deposition of immune-complexes, and restricted functionality. Liver organoids, which utilize stem cells instead of ‘impractical’ adult hepatocytes, may be a solution for the development of a complex bioartificial liver. Recent studies have explored the benefits of differentiating mature hepatocytes from stem cells inside a bioreactor. When the use of human-induced Hepatocytes (hiHeps) was investigated in mouse and pig models of liver failure, liver failure markers were decreased, hepatocyte function indicated by albumin synthesis improved, and survival time increased. Bioartificial liver treatment may decrease the infiltration of inflammatory cells into liver tissue by down-regulating pro-inflammatory cytokines.

show abstract

Section: Alternative Therapy For Esld: Hepatocyte Transplantationmentioning

confidence: 99%

Section: Alternative Therapy For Esld: Hepatocyte Transplantationmentioning

confidence: 99%